Atai Life Sciences N.V. Q2 FY2021 Earnings Call

· Earnings call transcript and AI-powered summary

  • IPO & Funding: ATAI Life Sciences successfully completed its IPO in June 2021, raising $259 million. As of June 30, 2021, the company had a strong cash position of $453.6 million (up from $97.2 million on December 31, 2020).
  • Business Strategy: ATAI operates a decentralized drug development model with 11 programs and 6 enabling technologies under management. The company uses a milestone-based capital allocation strategy and emphasizes compounds with prior evidence in humans.
  • Pipeline & R&D Catalysts: 18 R&D milestones expected in next 18 months. Key upcoming catalysts include:
    • COMPASS Pathways: Phase 2B top line data for COMP360 (psilocybin) in TRD expected in Q4 2021.
    • Recognify Life Sciences: Phase 2A data for RL-007 in CIAS expected by end of 2021.
    • Perception Neuroscience: Phase 2a trial of PCN-101 (ar-ketamine) to begin in Q3 2021.
    • DemeRx: Phase 1/2a trial of DMX-1002 (ibogaine for OUD) initiated in Q3 2021; safety data expected early 2022.
  • Ongoing Trials & Updates:
    • GRX-917 (anxiolytic): Phase 1 trial ongoing; top-line data expected early 2022.
    • RL-007: Exploring safety and pro-cognitive biomarkers in CIAS. Potential P300 and EEG signal markers being evaluated.

Continue Reading

Unlock the full AI-powered summary with key highlights, financial performance, and analyst Q&A.

Upgrade to Professional
Operator: Good morning and welcome the ATAI Life Sciences Second Quarter 2021 Financial Results and Corporate Update Conference Call. Currently all participants are in listen only mode. This call is being webcast live via the news and events section of the company's website at www.atai.life and is being recorded. For opening remarks I would like to introduce Greg Weaver, Chief Financial Officer of ATAI Life Sciences. Please go ahead. Greg Weaver: Thank you and good morning. Welcome to our second quarter 2021 ATAI Life Sciences financial results and corporate update conference call. The press release reporting our financial results is available in the investors and media section of our website at www.atai.life and our quarterly report on Form-10Q ended June 30th 2021 will file today with the SEC. Joining me today are Florian Brand, our co-founder and CEO. Dr. Srinivas Rao, our Co-Founder and Chief Scientific Officer; and Christian Angermayer, Founder and Chairman. During today's call, we'll be making certain forward looking statements that are intended to be covered by the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. While these statements represent management's current expectations of projections about future results, and performance as of today, the ties actual results are subject to many risks and uncertainties that could cause actual results to differ materially from those expectations. In addition to any risks highlighted during the ca

Continue Reading

Unlock the full earnings call transcript with speaker labels and formatted dialogue.

Upgrade to Professional